Breaking News on Biopharmaceutical Development & Manufacturing

Headlines > Bio Developments

PPD expands Virginia vaccine lab with an eye on assays

24-May-2017 - Pharmaceutical Product Development LLC (PPD) has expanded its vaccine research services lab in Richmond, Virginia.

JSR Corporation invests $30m in CDMO facilities

24-May-2017 - JSR Corporation subsidiary KBI Biopharma is expanding its facilities in Durham, North Carolina and Boulder, Colorado, US, to respond to client needs.

‘Dual-warhead’ a key differentiator for ADCs, says Synaffix

17-May-2017 - Antibody-drug conjugate (ADC) technology developer Synaffix has been granted a US patent for its dual-warhead HydraSpace platform.

Norgine increases portfolio in Merus acquisition

16-May-2017 - European Norgine B.V. has agreed to acquire all issued and outstanding shares of Merus Labs International in cash for $342m (€309.6).

Takeda teams with GammaDelta to develop novel cell therapies

12-May-2017 - Takeda has teamed up with GammaDelta Therapeutics to develop novel T-cell-based therapies in a deal that includes an option to buy the year-old UK biotech.

Avantor to spend $6.4bn on VWR acquisition

12-May-2017 - Avantor has agreed to purchase independent laboratory product, supply chain and service provider VWR for approximately $6.4bn (€5.9bn), reflecting a share price of $33.25.

Vision on the Horizon: Horizon Pharma acquires River Vision’s Thyroid Eye Disease mAb

12-May-2017 - Horizon Pharma has announced it will acquire River Vision Development Corp. and its fully human monoclonal antibody (mAb), teprotumumab (RV001).

Pfizer expands hemophilia gene therapy pipeline with $720m Sangamo deal

12-May-2017 - Pfizer has upped its presence in the gene therapy space through collaboration with Sangamo Therapeutics on its programmes worth up to $720m.

Brammer invests in commercial-ready gene therapies

10-May-2017 - Brammer Bio says its commercial-scale gene therapy manufacturing facility in Cambridge, Massachusetts, US, will open in the second half of 2017.

Selexis’ Swiss investment in mammalian cell lines

09-May-2017 - Selexis SA has announced its cell line development laboratory will open this week in Geneva, Switzerland.

Amgen funds development of intracellular drugs

09-May-2017 - Amgen has teamed with Feldan Therapeutics and Elasmogen in an exclusive research agreement to develop and deliver intracellular biologics.

SSB invests in mAb and biosimilar analysis

05-May-2017 - Sartorius Stedim Biotech (SSB) has launched a range of chemistry testing services in its subsidiary Scotland-based facility, Sartorius Stedim BioOutsource (SSBO), to focus on biosimilars and monoclonal antibodies (mAbs).

BPI Europe 2017

Cost-cutting oral vaccine tech will make Vaxart less reliant on CMO

04-May-2017 - Vaxart says its tablet delivery platform has simplified vaccine production so significantly it may bring manufacturing currently contracted to Lonza back in-house.

Astrazeneca and Pieris team to develop mAb-like drugs for lung diseases

03-May-2017 - Astrazeneca has teamed up with Pieris Pharmaceuticals Inc to develop antibody like mini proteins for the treatment of lung diseases.

Daiichi Sankyo pumping $135m into antibody-drug conjugate production

28-Apr-2017 - Daiichi Sankyo will plough ‎¥15bn ($135m) into three Japanese manufacturing facilities to support its antibody-drug conjugate pipeline.


CHO stopper? Biogen looks to alternative cell lines for future of bioproduction

28-Apr-2017 - The Chinese hamster ovary (CHO) cell line is not the future for biomanufacturing says Biogen, which will publish results from a study of alternative hosts later this year.

Thermo Fisher collaborates to establish single-use and automation site in China

27-Apr-2017 - Mab-Venture Biopharma has entered a collaboration to establish an antibody development and production plant in China incorporating Thermo Fisher’s single-use bioreactors and SmartFactory automated technology.


Messenger RNA a ‘game-changer’ for vaccine industry, Sanofi Pasteur

26-Apr-2017 - Sanofi Pasteur says heavy investment in messenger RNA (mRNA) is warranted as such technology could revolutionise vaccine development and manufacturing.

A cracking new method: Valneva and Bavarian Nordic’s hen egg alternative

21-Apr-2017 - European biotech companies Valneva and Bavarian Nordic have entered a commercial agreement to develop cell-based vaccines using production methods that are faster and cheaper than methods that use hen’s eggs. ...

News in brief

Synpromics announces £5.2M British investment in gene therapy tech

19-Apr-2017 - Scottish synthetic biology firm Synpromics has received £5.2M ($6.6M) to enhance its synthetic promoter design technology used in gene therapy development.

1st Stem Cell Community day in Germany

For stem cells 'the process is the product,' says Pluristem

19-Apr-2017 - Manufacturing tweaks have severe effects on the quality and yield of stem cells, says Pluristem which has successfully scaled-up production through a decade of process development evolution.

Pork firm Smithfield sets up organ supply unit for regenerative meds sector

13-Apr-2017 - Smithfield Foods Inc. has tasked a new bioscience unit with turning byproducts from its pork business into supplies for regenerative meds and drug firms.

Sanfilippo syndrome gene therapy could be filed in US next year, Abeona

11-Apr-2017 - Abeona Therapeutics says it plans to file its single injection adeno-associated virus (AAV) gene therapy for Sanfilippo syndrome in the US in late 2018.

RESPECT: find out what it means to ADCs, says Eisai subsidiary

07-Apr-2017 - Morphotek Inc has launched an antibody-drug conjugate (ADC) services business incorporating its RESPECT site-specific conjugation technology and eribulin-linker toxin platform.

Shire success will support polysialic acid drug delivery platform, says Xenetic

06-Apr-2017 - Xenetic Biosciences says success for Shire’s haemophilia A candidate SHP656 will validate its PolyXen drug delivery technology platform and could net the firm up to $100m.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...